Recursion Pharmaceuticals Inc (RXRX)
6.40
+0.08
(+1.27%)
USD |
NASDAQ |
Nov 01, 16:00
6.405
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Debt to Equity Ratio: 0.0531 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.0531 |
| March 31, 2024 | 0.0028 |
| December 31, 2023 | 0.0025 |
| September 30, 2023 | 0.0042 |
| June 30, 2023 | 0.0039 |
| March 31, 2023 | 0.0043 |
| December 31, 2022 | 0.0013 |
| September 30, 2022 | 0.0017 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.0016 |
| March 31, 2022 | 0.0014 |
| December 31, 2021 | 0.0013 |
| September 30, 2021 | 0.0012 |
| June 30, 2021 | 0.0195 |
| March 31, 2021 | -0.0536 |
| December 31, 2020 | -0.0605 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-0.0605
Minimum
Dec 2020
0.0531
Maximum
Jun 2024
-0.001
Average
0.0017
Median
Sep 2022
Debt to Equity Ratio Benchmarks
| Eli Lilly and Co | 2.185 |
| Pfizer Inc | 0.7831 |
| Revance Therapeutics Inc | -3.319 |
| Twist Bioscience Corp | 0.00 |
| NovaBay Pharmaceuticals Inc | -1.128 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 775.86M |
| Total Liabilities (Quarterly) | 191.41M |
| Shareholders Equity (Quarterly) | 584.45M |
| Current Ratio | 6.068 |
| Net Debt Paydown Yield | -0.28% |